Markus G Manz
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.
Hilberink J, van Zeventer I, Chitu D, Pabst T, Klein S, Stussi G, Griskevicius L, Valk P, Cloos J, van de Loosdrecht A, Breems D, van Lammeren-Venema D, Boersma R, Jongen-Lavrencic M, Fehr M, Hoogendoorn M, Manz M, Söhne M, van Marwijk Kooy R, Deeren D, van der Poel M, Legdeur M, Tick L, Chalandon Y, Ammatuna E, Blum S, Löwenberg B, Ossenkoppele G, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK), Huls G. Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine. Blood Cancer J 2023; 13:93.
Jun 19, 2023Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.
Jun 19, 2023Blood Cancer J 2023; 13:93
Hilberink Jacobien R, van Zeventer Isabelle A, Chitu Dana A, Pabst Thomas, Klein Saskia K, Stussi Georg, Griskevicius Laimonas, Valk Peter J M, Cloos Jacqueline, van de Loosdrecht Arjan A, Breems Dimitri A, van Lammeren-Venema Daniëlle, Boersma Rinske, Jongen-Lavrencic Mojca, Fehr Martin, Hoogendoorn Mels, Manz Markus G, Söhne Maaike, van Marwijk Kooy Rien, Deeren Dries, van der Poel Marjolein W M, Legdeur Marie-Cecile J C, Tick Lidwine W, Chalandon Yves, Ammatuna Emanuele, Blum Sabine, Löwenberg Bob, Ossenkoppele Gert J, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK), Huls Gerwin
Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort
Brune M, Cogliatti S, Ossenkoppele G, Löwenberg B, Rudolf C, Li Q, Passweg J, Mazzuchelli L, Medinger M, Tzankov A, Fehr M, Grobholz R, Stussi G, Lundberg P, Vela V, Heim D, Manz M, Haralambieva E, Pabst T, Banz Y, Bargetzi M, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK). Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort. Ann Hematol 2021; 100:1169-1179.
Mar 2, 2021Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort
Mar 2, 2021Ann Hematol 2021; 100:1169-1179
Brune Magdalena M, Cogliatti Sergio B., Ossenkoppele Gert J, Löwenberg Bob, Rudolf Christina Biaggi, Li Qiyu, Passweg Jakob, Mazzuchelli Luca, Medinger Michael, Tzankov Alexandar, Fehr Martin, Grobholz Rainer, Stussi Georg, Lundberg Pontus, Vela Visar, Heim Dominik, Manz Markus G, Haralambieva Eugenia, Pabst Thomas, Banz Yara, Bargetzi Mario, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK)
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
Ossenkoppele G, Porkka K, Cornelissen J, Kuball J, Fischer T, Legdeur M, Hoogendoorn M, Breems D, Moors I, van Lammeren-Venema D, Silzle T, Juliusson G, Meyer P, Floisand Y, Manz M, van Elssen C, Valk P, Cloos J, Passweg J, Huls G, Janssen J, Gjertsen B, Höglund M, Gregor M, Veelken H, van Marwijk Kooy M, Jongen-Lavrencic M, Tick L, Griskevicius L, Vellenga E, Spertini O, Biemond B, Gradowska P, Maertens J, Pabst T, Vekemans M, van der Velden W, Westerweel P, Gadisseur A, Klein S, Bargetzi M, van Esser J, de Weerdt O, Deeren D, Graux C, Michaux L, Beverloo B, Löwenberg B. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. Blood Adv 2021; 5:1110-1121.
Jan 23, 2021Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
Jan 23, 2021Blood Adv 2021; 5:1110-1121
Ossenkoppele Gert J, Porkka Kimmo, Cornelissen Jan, Kuball Juergen, Fischer Thomas, Legdeur Marie-Cecile J C, Hoogendoorn Mels, Breems Dimitri A, Moors Ine, van Lammeren-Venema Daniëlle, Silzle Tobias, Juliusson Gunnar, Meyer Peter, Floisand Yngvar, Manz Markus G, van Elssen Catharina H M J, Valk Peter J M, Cloos Jacqueline, Passweg Jakob, Huls Gerwin, Janssen Jeroen J W M, Gjertsen Bjorn T, Höglund Martin, Gregor Michael, Veelken Hendrik, van Marwijk Kooy Marinus, Jongen-Lavrencic Mojca, Tick Lidwine W, Griskevicius Laimonas, Vellenga Edo, Spertini Olivier, Biemond Bart J, Gradowska Patrycja, Maertens Johan, Pabst Thomas, Vekemans Marie-Christiane, van der Velden Walter J F M, Westerweel Peter E, Gadisseur Alain, Klein Saskia K, Bargetzi Mario, van Esser Joost W J, de Weerdt Okke, Deeren Dries, Graux Carlos, Michaux Lucienne, Beverloo Berna, Löwenberg Bob
Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013
Schnegg-Kaufmann A, Bonadies N, Arndt V, Stussi G, Passweg J, Chalandon Y, Spertini O, Hess U, Bargetzi M, Efthymiou A, Gregor M, Manz M, Rovó A, Baldomero H, Feller A, NICER Working Group. Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013. Cancer Epidemiol 2017; 52:55-62.
Dec 7, 2017Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013
Dec 7, 2017Cancer Epidemiol 2017; 52:55-62
Schnegg-Kaufmann Annatina, Bonadies Nicolas, Arndt Volker, Stussi Georg, Passweg Jakob R, Chalandon Yves, Spertini Olivier, Hess Urs, Bargetzi Mario, Efthymiou Anna, Gregor Michael, Manz Markus G, Rovó Alicia, Baldomero Helen, Feller Anita, NICER Working Group
Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo
Karsunky H, Merad M, Cozzio A, Weissman I, Manz M. Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J Exp Med 2003; 198:305-13.
Jul 21, 2003Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo
Jul 21, 2003J Exp Med 2003; 198:305-13
Karsunky Holger, Merad Miriam, Cozzio Antonio, Weissman Irving L, Manz Markus G